Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Institutional & Insider Ownership
69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Biorestorative Therapies and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
| Orchestra BioMed | -166.96% | -157.46% | -60.18% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biorestorative Therapies | $360,000.00 | 23.94 | -$14.24 million | ($1.07) | -0.32 |
| Orchestra BioMed | $32.72 million | 6.99 | -$52.70 million | ($0.97) | -3.94 |
Biorestorative Therapies has higher earnings, but lower revenue than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Biorestorative Therapies has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Biorestorative Therapies and Orchestra BioMed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biorestorative Therapies | 1 | 0 | 0 | 0 | 1.00 |
| Orchestra BioMed | 1 | 1 | 5 | 0 | 2.57 |
Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 256.02%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Biorestorative Therapies.
Summary
Orchestra BioMed beats Biorestorative Therapies on 8 of the 14 factors compared between the two stocks.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
